drugset / Trial / NCT00820794

A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects

NCT00820794

Phase 1 Withdrawn Pfizer
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to investigate if PD 0332334 affects the pharmacokinetics of lithium by co-administering both drugs to healthy adults.

Timeline

Start
2009-05
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject IMAGABALIN Other / unclassified 225 mg Oral
Subject Lithium Unknown 300 mg Oral